Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$5.05 USD
+0.59 (13.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.05 USD
+0.59 (13.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Champions Oncology (CSBR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Champions Oncology (CSBR) stock based on the movements in the options market lately.
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200.00% and 2.30%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Champions Oncology, Inc. (CSBR) Reports Next Week: What You Should Expect
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strength Seen in Champions Oncology, Inc. (CSBR): Can Its 15.3% Jump Turn into More Strength?
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analysts Estimate Champions Oncology, Inc. (CSBR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
The Truth About Market Timing - October 06, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%
by Zacks Equity Research
Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
The Keys to Successfully Timing the Markets - September 15, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
The Keys to Successfully Timing the Markets - August 18, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
When Does Market Timing Actually Work? - July 29, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Timing the Market, Is it Possible? - July 07, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
The Truth About Market Timing - June 17, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Timing the Market, Is it Possible? - April 28, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Yes, You Can Time the Market. Find out How - April 02, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?